Clinical Trial Update: Efficacy Study of DX-88 (Ecallantide) to Treat Acute Attacks of Hereditary Angioedema (HAE) [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating DX-88 (ecallantide) for acute attacks of hereditary angioedema has completed with results posted in 2010.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hereditary Angioedema

Drugs mentioned

• DX-88 (ecallantide) (ecallantide)

Snippet

Sponsor: Shire | Conditions: Hereditary Angioedema (HAE) | Phase 3 | Status: COMPLETED | Results posted: 2010-05-04